 With the COVID vaccine, Pfizer has been struggling to find its next big thing. This could be it. Today, Pfizer says it's moving forward with tests on a weight loss treatment that, unlike obesity drugs already on the market, doesn't have to be injected. It's a daily pill. Analysts point out that while it's still early, there's a huge potential upside for Pfizer, whose shares are up 3%.